EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Alpha lipoic acid: advancing insights in diabetic neuropathy through updated systematic review and meta-analysis

Susmita Das, Gollapalle Lakshminarayanashastry Viswanatha, Krishnadas Nandakumar, Anoop Kishore, Shylaja Hanumanthappa

Exploration of Neuroprotective Therapy · 05.12.2025 · 5

DOI: 10.37349/ent.2025.1004125 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Exploration of Neuroprotective Therapy, online erschienen am 05.12.2025. Verfasst von Susmita Das und 4 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aims to assess oral alpha lipoic acid’s (ALA’s) safety and effectiveness in managing diabetic neuropathy.

Methods

A thorough search of the literature was conducted using PubMed, Google Scholar, and Embase databases, and the study was performed as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results

Based on inclusion and exclusion criteria, nine randomized controlled trials (RCTs) comprising 1,345 subjects were selected. The results showed that ALA has shown significant reduction in glycated hemoglobin (HbA1C) [inverse variance (IV): –0.66, (–0.81 → –0.51) at 95% CI, p < 0.00001, I2 = 92%], neuropathy impairment score (NIS) [IV: –1.19, (–2.28 → –0.09) at 95% CI, p = 0.03, I2 = 58%], along with improving the neuropathy symptoms and change (NSC) number [IV: –0.18, (–0.35 → –0.01) at 95% CI, p = 0.04, I2 = 0%], NSC severity score [IV: –0.65, (–0.83 → –0.48) at 95% CI, p < 0.00001, I2 = 89%], total severity score (TSS) [IV: –0.43, (–0.59 → –0.27) at 95% CI, p < 0.00001, I2 = 98%], neurological disability score (NDS) [IV: –0.72, (–1.03 → –0.40) at 95% CI, p < 0.00001, I2 = 98%], vibration perception threshold (VPT) [IV: –0.35, (–0.50 → –0.19) at 95% CI, p < 0.0001, I2 = 96%] and global satisfaction [Mantel-Haenszel (M-H) odds ratio (OR): 3.51, (1.06 → 11.61) at 95% CI, p = 0.04, I2 = 72%] when compared to the control or placebo group. However, ALA has not shown significant changes in motor nerve conduction velocity (MNCV) score [IV: 0.26, (–0.44 → 0.96) at 95% CI, p = 0.47, I2 = 49%] and NIS-low limb (NIS-LL) [IV: –0.58, (–1.35 → 0.19) at 95% CI, p = 0.14, I2 = 0%] when compared to the placebo group.

Discussion

Based on the available moderate to high-quality evidence, we can conclude that oral administration of ALA at doses of 600–1,800 mg may be beneficial in improving/alleviating the symptoms resulting from diabetic neuropathy.

Zitieren

APA

Das, S., Viswanatha, G. L., Nandakumar, K., Kishore, A., & Hanumanthappa, S. (2025). Alpha lipoic acid: advancing insights in diabetic neuropathy through updated systematic review and meta-analysis. Exploration of Neuroprotective Therapy, 5. https://doi.org/10.37349/ent.2025.1004125

Vancouver

Das S, Viswanatha GL, Nandakumar K, Kishore A, Hanumanthappa S. Alpha lipoic acid: advancing insights in diabetic neuropathy through updated systematic review and meta-analysis. Exploration of Neuroprotective Therapy. 2025;5. doi:10.37349/ent.2025.1004125

BibTeX
@article{Das2025,
  author = {Das, Susmita and Viswanatha, Gollapalle Lakshminarayanashastry and Nandakumar, Krishnadas and Kishore, Anoop and Hanumanthappa, Shylaja},
  title = {Alpha lipoic acid: advancing insights in diabetic neuropathy through updated systematic review and meta-analysis},
  journal = {Exploration of Neuroprotective Therapy},
  year = {2025},
  volume = {5},
  doi = {10.37349/ent.2025.1004125}
}
Kostenlos starten →